Clinical Trials in Baltimore

Showing 2101-2120 of 20,142 trials

DAY101 In Gliomas and Other Tumors

NCT03429803

This research study is studying a drug Tovorafenib/DAY101 (formerly TAK-580, MLN2480) as a possible treatment a low-grade glioma that has not responded to other treatments. The name of the study drug involved in this study is: • Tovorafenib/DAY101 (formerly TAK-580, MLN2480)

Low-grade Glioma

Karen D. Wright, MD44 participantsStarted Feb 2018

Los Angeles, California, United States • San Diego, California, United States • San Francisco, California, United States +12 more locations

COMPLETEDNA< 1 mile

A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

NCT05785832

A randomized controlled trial (RCT) to assess the safety and efficacy of use of Control-IQ+ technology in adults with type 2 diabetes using basal-bolus insulin therapy.

Type 2 Diabetes Treated With Insulin

Tandem Diabetes Care, Inc.319 participantsStarted Jun 2023

Newport Beach, California, United States • Atlanta, Georgia, United States • Idaho Falls, Idaho, United States +18 more locations

DAY101 In Gliomas and Other Tumors

A Randomized Trial Evaluating Control-IQ+ Technology in Adults With Type 2 Diabetes

Find Trials by Condition in Baltimore

Developing a Nationwide Registry to Track Longitudinal Clinical Outcomes of Corneal Surgery and Disease

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial

Secondary Pulmonary Hypertension in Adults With Sickle Cell Anemia

Addictions Neuroclinical Assessment (ANA)

COVID-19 Experiences in the SELF Cohort

Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients

Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)

A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

Alcohol-ROC-Training

CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy